Companies Dominating the Benign Prostatic Hyperplasia Prostate Treatment Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Cardinal Health Inc.
- NxThera, Inc.
- Veru, Inc.
- Teleflex Incorporated
- Eli Lily & Company
- Sanofi S.A.
- GSK plc
- Mylan N.V.
- AbbVie Inc.
Key strategies adopted by the benign prostatic hyperplasia prostrate treatment market include product launches, strategic partnerships and acquisitions, and geographical expansions. Additionally, players are focusing on regulatory approvals, patient awareness campaigns, and affordable pricing strategies to enhance market penetration and gain a competitive edge. Some of these companies are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of benign prostatic hyperplasia prostate treatment is estimated at USD 8.22 billion.
The benign prostatic hyperplasia prostate treatment market size was over USD 7.86 billion in 2024 and is likely to cross USD 16.09 billion by the end of 2037, growing at more than 5.8% CAGR during the forecast period i.e., between 2025-2037. Higher prevalence of benign prostatic hyperplasia (BPH), developing medical technology across the globe, increasing healthcare expenditure per capita, and spiking cases of urinary tract infection will drive the market growth.
North America is projected to account for majority industry share by 2037, ascribed to rising geriatric population, an increasing unhealthy lifestyle, and a higher prevalence of benign prostatic hyperplasia.
The major players in the market include Pfizer Inc., Cardinal Health Inc., NxThera, Inc., Veru, Inc., Teleflex Incorporated, Eli Lily & Company, Sanofi S.A., GSK plc, Mylan N.V., AbbVie Inc.
